George Sledge Jr., MD, Oncology, Palo Alto, CA, Stanford Health Care

GeorgeWSledgeJr.MD

Oncology Palo Alto, CA

Hematologic Oncology

Professor of Medicine, Indiana University

Dr. Sledge is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sledge's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center - San Antonio
    University of Texas Health Science Center - San AntonioFellowship, Medical Oncology, 1981 - 1983
  • St Louis University School of Medicine
    St Louis University School of MedicineResidency, Internal Medicine, 1977 - 1980
  • Tulane University School of Medicine
    Tulane University School of MedicineClass of 1977

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2013 - 2022
  • IN State Medical License
    IN State Medical License 1983 - 2013
  • LA State Medical License
    LA State Medical License 1977 - 1983
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research 
    The University of Texas, M. D. Anderson Cancer Center, San Diego, California - 1/31/2013

Press Mentions

  • Urges Commitment to Conquer Metastatic Breast Cancers
    Urges Commitment to Conquer Metastatic Breast CancersOctober 14th, 2019
  • Now with Survival Benefit, CDK4/6 Inhibitors in Breast Cancer
    Now with Survival Benefit, CDK4/6 Inhibitors in Breast CancerOctober 10th, 2019
  • Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup
    Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer SubgroupSeptember 30th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations